Background-6-Mercaptopurine and its prodrug azathioprine are effective medications for refractory inflammatory bowel disease. However, use of these drugs has been limited by concerns about their toxicity. Colonic delivery of azathioprine may reduce its systemic bioavailability and limit toxicity. Aim-To determine the bioavailability of 6-mercaptopurine after administration of azathioprine via three colonic delivery 
6-Mercaptopurine (6MP) and its prodrug azathioprine (AZA) have been used in the treatment of inflammatory bowel disease (IBD) for over 25 years. Multiple controlled trials and a recent meta analysis support the efficacy of 6MP and AZA in Crohn's disease. [1] [2] [3] [4] [5] [6] [7] Controlled trials also support the use of AZA in ulcerative colitis, the most recent by Hawthorne and colleagues. [8] [9] [10] [11] [12] However, use of 6MP and AZA for IBD has been limited by concerns about their toxicity, including dose related leucopenia, which is seen in 2-5% of patients treated in the long term with 6MP or AZA for IBD. 13 14 Colonic drug delivery has the potential advantage of providing a local therapeutic effect with reduced systemic bioavailability, and thereby limited toxicity. This mode of delivery has been effectively used with both mesalamine and corticosteroids in patients with IBD. 15 The aim of this study was to determine the bioavailability of 6MP after AZA delivery by three different colonic delivery methods. We studied AZA pharmacokinetics by determining 6MP bioavailability rather than AZA bioavailability because of the availability of reliable techniques for measuring plasma 6MP concentrations. In addition, 6MP is the more biologically relevant molecule, as AZA functions as a prodrug for 6MP. After absorption, AZA is quickly converted to 6MP via non-enzymatic attack on the bond between the imidazole ring and the 6MP molecule by sulphydryl containing compounds such as glutathione.16 6MP is further metabolised to the compounds with immunomodulatory activity, the 6-thioguanine nucleotides (6TGN). 17 Demonstration of reduced 6MP bioavailability after colonic AZA delivery would provide the basis for a therapeutic clinical trial of this method of AZA administration in patients with IBD.
Methods

Subjects
Twenty four healthy human volunteers were recruited from January 1994 to August 1994 to participate in a study ofAZA pharmacokinetics after four different delivery methods (oral, delayed release oral, hydrophobic rectal foam, hydrophilic rectal foam). The study protocol was approved by the Institutional Review Board of the Mayo Clinic and written informed consent was obtained prior to subject participation. Screening physical examination and laboratory studies (complete blood count, chemistry panel, and urine analysis) were performed. Prior to study entry, the erythrocyte thiopurine methyltransferase (TPMT) activity was determined in all subjects. This enzyme is critical for the catabolic metabolism of 6MP.
In the general population TPMT activity has a trimodal distribution: homozygous low TPMT activity (<5 0 U/ml RBC) occurs at a frequency of 03%; heterozygous low TPMT activity (5.0-13.7 U/mI RBC) occurs at a frequency of 11 1/o%; and normal TPMT activity (13.8-25 Results Twenty four subjects were enrolled and randomised to one of four possible non-intravenous administrations of AZA (oral, DRO, HBF, and HPF). There were no statistically significant differences in age, body weight, and TPMT activity between the four groups ( Table I ).
The AUC, CL, Vdss, and T1/2 were used as indices for comparison of the intravenous studies among the four groups by the KruskalWallis test (Table II) . There were no statistically significant differences among the groups, indicating that the baseline intravenous parameters of the groups were similar. For nonintravenous studies, the parameters AUC, F, and Cm., were compared between groups by the Kruskal-Wallis test (Table III) Figure 2 depicts the model derived mean intravenous concentration versus time curves for each of the delivery groups. Also plotted for the oral group is the mean observed concentration versus time curve. For the DRO, HBF, and HPF groups are plotted the observed concentrations, with different symbols representing individual subjects. We chose to present the data in this manner because there were not enough data points for the non-intravenous --t studies of the DRO, HBF, and HPF groups to 4 5 create meaningful curves. The rectal foam preparations were well ation versus tolerated. Ten of 12 subjects retained the Iministration foam for greater than six hours. One subject reported expelling the hydrophobic foam after one hour and another reported expelling the etween the hydrophobic foam after two hours. The subject Dns. When who reported expelling the foam after one hour rwise com-did not have detectable absorption. The were strong subject who reported expelling the foam after al formula-two hours had a Cmax of 2.35 ng/ml at three the F and hours. No adverse reactions to any of the drug wever, the preparations were reported.
iificance at 4 for F and ). By inspection, the TmaX of Discussion lation was greater than the This study shows that there were significant {IBP, and HPF formulations. differences in bioavailability of 6MP after centration values after intra-dosing with oral, DRO, and rectal delivery forition of AZA for each subject mulations of AZA. When Wilcoxon rank sum to a two compartment model pairwise comparison is performed between the groups, the bioavailabilities of 6MP after the Delayed release oral DRO formulation and rectal delivery formulations were significantly less than after the standard oral AZA. 1-3) , 16.9 ng/ml (8.3-42) , and 47% (27-83) after a 50 mg oral dose. The results of the two studies suggest that the uraemic subjects may have a greater CL and Vdss for 6MP.
Colonic administration of corticosteroids and 5-aminosalicylate has been effectively utilised in patients with IBD. In the case of corticosteroids, reduced toxicity has been seen with colonic delivery. This decreased toxicity is due to reduced bioavailability. Several types of colonic drug delivery systems are currently available, including enemas15; rectal foams27; and delayed release oral formulations in the form of Eudragit coated capsules, which dissolve at pH 7 in the terminal ileum.23
To date, information regarding colonic delivery of AZA and 6MP is limited to two pharmacokinetic studies of 6MP administered as a rectal suppository to rats28 and to children.29
In the rat study, a hydrophilic macrogol base suppository resulted in significantly higher bioavailability than a hydrophobic oleaginous base (witepsol H-1 5) suppository. In children given 6MP via standard oral and hydrophilic macrogol suppository routes, the hydrophilic base suppository had a mean AUC that was 4.4 times greater than the mean AUC for the oral dose. Rectal suppositories are delivered to a watershed region of the intestinal circulation where venous drainage is both portal and systemic. Direct systemic absorption of 6MP would probably result in increased bioavailability because first pass metabolism in the liver would be avoided. In contrast, our data show that when foam AZA preparations are delivered to the entire left colon (proximal to the rectum), 6MP bioavailability is negligible.
Our data show reduced 6MP bioavailability after colonic administration of AZA via a DRO capsule or rectal foam. There are several potential factors contributing to this finding. The most probable is that the absorption of AZA across the colonic mucosa is reduced compared with absorption across gastric and small intestinal mucosa. This may be due to absence of specific transport mechanisms or differing rates of passive absorption. AZA and 6MP may be more completely metabolised in the colonic mucosa than in the mucosa of the more proximal gastrointestinal tract After absorption, AZA is quickly converted to 6MP in plasma. This conversion occurs as the result of non-enzymatic attack by sulphydryl containing compounds such as glutathione on the bond between the 6MP molecule and the imidazole ring of AZA.16 Glutathione is present in every mammalian cell, including colonic epithelial cells and lymphocytes. 33 Previous studies have shown that lymphocytes contain the enzymes necessary to convert 6MP to the active metabolites, the 6TGNs.34 It is, therefore, reasonable to hypothesise that topical delivery of AZA will result in local immunosuppressive effects on colonic lymphocytes. In support of the hypothesis that local delivery of 6MP can be more efficacious compared with systemic delivery, use of parenteral 6MP infused into the renal artery resulted in prolonged survival and reduced toxicity compared with systemic intravenous 6MP in canine renal allograft recipients.35 36 Our study shows that colonic delivery of AZA results in significantly lower 6MP bioavailability than standard oral AZA. Colonic delivery of AZA could potentially reduce the drug's toxicity by reducing systemic exposure to 6MP. In addition, this topical form of AZA administration may permit delivery of higher, locally concentrated doses to the colon. The therapeutic potential of colonic AZA delivery should be investigated in patients with IBD.
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